<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245453</url>
  </required_header>
  <id_info>
    <org_study_id>HMR3647A6004</org_study_id>
    <nct_id>NCT00245453</nct_id>
  </id_info>
  <brief_title>Outpatient Registry Trial of Respiratory Tract Infections in Adults</brief_title>
  <official_title>Randomized Aseptic Pharmacokinetic Pharmacodynamic Outpatient Registry Trial of Respiratory Tract Infections in Adults (RAPPORT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CPL Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CPL Associates</source>
  <brief_summary>
    <textblock>
      To measure the speed of bacterial eradication from the respiratory tract after administration
      of azithromycin or telithromycin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To Evaluate the relationship between rate of S. pneumoniae killing in sputum, PK/PD, and
      clinical response of oral telithromycin and azithromycin in patients with AECB or CAP and to
      determine if there is a difference in the rates of infection site bacterial killing (as
      described above) between these 3 antibiotics against penicillin- and erythromycin-resistant
      S.pneumoniae
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Terminated by sponsor
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to bacterial eradication</measure>
    <time_frame>11-18 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacteriologic outcome</measure>
    <time_frame>11-18 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pneumonia, Bacterial</condition>
  <condition>Bronchitis, Chronic</condition>
  <arm_group>
    <arm_group_label>1 Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Clarythromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Telithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
    <description>250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5</description>
    <arm_group_label>1 Azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telithromycin</intervention_name>
    <description>400 mg tablets; 2 tablets once daily (QD) for 5 days</description>
    <arm_group_label>3 Telithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarythromycin</intervention_name>
    <description>500 mg extended release tablets; 2 tablets QD for 7 days</description>
    <arm_group_label>2 Clarythromycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, either males or non-pregnant females, aged 18 to 75 years of age with
             clinical findings of CAP or AECB who are amenable to serial nasopharyngeal and
             oropharyngeal sampling and having positive Binax-NOW tests indicating infection with
             Streptococcus pneumoniae

          -  Patients with a medical history and clinical findings consistent with a respiratory
             tract infection. A patient with advanced COPD, repeated exacerbations by history, a
             BINAX-NOW test consistent with S. pneumoniae and/or proven culture positivity for S.
             pneumoniae may be enrolled

          -  All patients (CAP or AECB) must produce purulent sputum and be positive on the Urinary
             BINAX-NOW assay.

          -  The female patient of child bearing potential must agree to use an accepted method of
             contraception (i.e., oral or implanted contraceptive with a barrier method, spermicide
             and barrier methods, or IUD). The patient must agree to continue with the same method
             throughout the study.

        Exclusion Criteria:

          -  Baseline sputum cultures known to be negative for S. pneumoniae, or negative urinary
             BINAX-NOW.

          -  Patients with a microbiologically documented pathogen known prior to inclusion to be
             resistant to any of the study medications.

          -  History of hypersensitivity to macrolides, azalides, ketolide antibiotics or history
             of serious hypersensitivity reaction to any drug.

          -  Pre-existing impaired hepatic function or impaired renal function CCL &lt;20ml/min

          -  Patients who will require on-study treatment with medications known to have
             contraindicated drug interactions with telithromycin

          -  Treatment with more than one dose of an antimicrobial prior to entry into the study

        Others as per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome J Schentag, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of New York at Buffalo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Paladino, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>State University of New York at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Kentucky Pulmonary Clinic</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>42240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore Research Associates</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cplassociates.com</url>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2005</study_first_submitted>
  <study_first_submitted_qc>October 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2005</study_first_posted>
  <last_update_submitted>July 27, 2015</last_update_submitted>
  <last_update_submitted_qc>July 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2015</last_update_posted>
  <keyword>pneumonia</keyword>
  <keyword>Spneumoniae</keyword>
  <keyword>bronchitis</keyword>
  <keyword>telithromycin</keyword>
  <keyword>azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Telithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

